Immune checkpoint inhibitor combinations—current and emerging strategies
Open Access
- 6 February 2023
- journal article
- editorial
- Published by Springer Nature in British Journal of Cancer
- Vol. 128 (8) , 1415-1417
Abstract
In an attempt to overcome resistance to immune checkpoint inhibitors (ICI), an ever-increasing number of trials are exploring combination treatment approaches. Outcomes of a novel ICI doublet presented by Desai and colleagues are discussed along with emerging novel strategies and a view to future ongoing rational trial design maximising patient benefit.Keywords
This publication has 9 references indexed in Scilit:
- ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 2022
- Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging conceptsJournal of Hematology & Oncology, 2022
- A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaClinical Cancer Research, 2022
- Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialNature Medicine, 2022
- Combination therapy with immune checkpoint inhibitors (ICIs); a new frontierCancer Cell International, 2022
- Development of Immunotherapy Combination Strategies in CancerCancer Discovery, 2021
- PD-L1 as a biomarker of response to immune-checkpoint inhibitorsNature Reviews Clinical Oncology, 2021
- Revisiting the PD-1 pathwayScience Advances, 2020
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upAnnals of Oncology, 2019